5 registrations that name citicoline as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 5 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 5 registrations
RecruitingNCT07089238
Evaluate the Effects of Citicoline on Mood in Healthy Adults
No phase
Kirin Holdings Company, Limited
About 90 people
Started Jul 31, 2025
In plain words A study of citicoline in people 21 to 65, run by Kirin Holdings Company, Limited. It plans to enroll about 90 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 65; healthy volunteers accepted. Conditions: Healthy.
Provide voluntary signed and dated informed consent.
Be in good health and able to participate as determined by medical history and routine blood chemistries.
Biological men and women between 21 and 65 years of age (inclusive).
Body Mass Index of 18.5-32.0 (inclusive).
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Citicoline; Placebo
Registered summary
The objective of this trial is to determine the effects of citicoline on mood in healthy Men and Women compared to a placebo.
Where, as registered
1 US site in 1 state.
RecruitingNCT07804498
CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium
Phase 2
University of Milano Bicocca
About 122 people
Started Jun 3, 2026
In plain words A Phase 2 study of citicoline in people 65 and older, run by University of Milano Bicocca. It plans to enroll about 122 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 65 and older. Conditions: Cognitive Decline; Delirium.
Individuals aged ≥65 who were admitted for a proximal hip fracture to the Orthogeriatric Unit and underwent hip fracture surgery (IRCCS San Gerardo dei Tintori Foundation, Monza)
Clinical diagnosis of delirium (arising from any cause), ascertained pre- or post-operatively using the 4AT score (cut-off ≥ 4/12)
Diagnosis of chronic vascular encephalopathy (corroborated by clinical documentation or previous cerebral imaging), i.e. evidence of neurological and cognitive disorder resulting from cerebrovascular accidents
Prognosis quoad vitam ≥ 3 months
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Citicoline
Registered summary
The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or attenuate cognitive decline in older adults who develop perioperative delirium during hospitalization for proximal hip fracture. Delirium is a frequent and severe complication in this population and is associated with cognitive and functional deterioration, institutionalization, and mortality. Participants will be randomly assigned (1:1) to receive citicoline 1000 mg/day for 6 months after discharge, or usual care. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT03949049
Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
Phase 3
Sherief Abd-Elsalam
About 40 people
Started Feb 1, 2019
In plain words A Phase 3 study of citicoline in people up to 1 month, run by Sherief Abd-Elsalam. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people up to 1 month. Conditions: Neonatal Hypoxia.
neonates with hypoxia.
The exclusion criteria are on the listing.
What it tests, as registered
Citicoline; Placebo
Registered summary
Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial
Where, as registered
No US site; Egypt (1).
RecruitingNCT03966170
Citicoline as Neuroprotector in Preterm
Phase 3
Sherief Abd-Elsalam
About 40 people
Started May 1, 2019
In plain words A Phase 3 study of citicoline in people up to 1 month, run by Sherief Abd-Elsalam. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people up to 1 month. Conditions: Pre-Term.
Preterm on CPAP or ventilator
The exclusion criteria are on the listing.
What it tests, as registered
Citicoline; Placebo oral tablet
Registered summary
Citicoline as neuroprotector in preterm
Where, as registered
No US site; Egypt (1).
Not yet recruitingNCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy
No phase
Khyber Girls Medical College
About 86 people
Starts Sep 1, 2026 (estimated)
In plain words A study of citicoline in people 0 hours to 24 hours, run by Khyber Girls Medical College. It plans to enroll about 86 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 0 hours to 24 hours. Conditions: Hypoxic Ischaemic Encephalopathy (HIE).
All inborn neonates diagnosed with APGAR score (Table 2) less then 8/10 at 5 min of life presenting to the emergency room within the first day of life.
Outborn babies admitted in the last 24 hours with history or clinical features of perinatal asphyxia.
The exclusion criteria are on the listing.
What it tests, as registered
Citicoline; Standard medical treatment
Registered summary
To determine the efficacy of citicoline in improving cerebral blood flow parameters and neurological status among neonates with hypoxic-ischemic encephalopathy using Doppler resistive index and Sarnat-Sarnat score after 72 hours of therapy.